Thomas H. Kean
Trade Performance Intelligence
Score: 1/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
5 flagsThomas H. Kean sold $1,001 - $15,000 in $JNJ on 2026-03-26, 1 day before HR8143 was introduced, a bill that could reduce brand-name drug sales.
Thomas H. Kean sold $15,001 - $50,000 in $CB on 2026-03-26, 14 days before HR8218 was introduced, a bill that could affect the insurance industry.
Thomas H. Kean sold $15,001 - $50,000 in $SPGI on 2026-03-26, 9 days after SJRES129 was introduced, a resolution that could increase compliance costs for credit reporting agencies.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AMCR | Amcor plc Ordinary Shares (AMCR) | $1K-$15K | $39.75 | $41.01 | +3.2% | Mar 31, 2026 |
| BUY | $LIN | Linde plc - Ordinary Shares (LIN) | $1K-$15K | — | — | — | Mar 26, 2026 |
| PARTIAL SELL | $CB | Chubb Limited Common Stock (CB) | $15K-$50K | — | — | — | Mar 26, 2026 |
| PARTIAL SELL | $PEP | Pepsico, Inc. (PEP) | $15K-$50K | $150.83 | $155.72 | +3.2% | Mar 26, 2026 |
| PARTIAL SELL | $SPGI | S&P Global Inc. Common Stock (SPGI) | $15K-$50K | — | — | — | Mar 26, 2026 |
| PARTIAL SELL | $FCNCA | First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) | $1K-$15K | $1,896.78 | $1,990.98 | +5.0% | Mar 26, 2026 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock (JNJ) | $1K-$15K | — | — | — | Mar 26, 2026 |
| PARTIAL SELL | $WAT | Waters Corporation Common Stock (WAT) | $1K-$15K | — | — | — | Mar 10, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The 'Protecting Americans from Unsafe Drugs Act of 2026' expands drug recall authority to all drugs, increasing compliance costs and liability for pharmaceutical manufacturers. This directly elevates operational expenses and risks for major pharmaceutical companies. The bill creates a significant headwind for the pharmaceutical sector.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
HR7879, the "SUPER BUGS Act of 2026," introduced on March 9, 2026, directs the Secretary of State to formulate a strategy for international collaboration on pandemic product development. This bill is in its early stages, referred to the House Committee on Foreign Affairs, and does not authorize specific funding, thus having no immediate direct financial impact on companies. However, it signals potential future policy that could benefit pharmaceutical and biotechnology companies by expanding global market access for qualified pandemic or epidemic products.
To ban the sale of nitrous oxide consumer products, and for other purposes.
HR7945, a bill to ban the sale of nitrous oxide consumer products, was referred to the House Committee on Energy and Commerce on March 16, 2026. This early-stage bill presents a potential future regulatory challenge for food and beverage companies, requiring product reformulation or market exit for affected segments. While the bill is in its initial stages, companies like Kraft Heinz, PepsiCo, Coca-Cola, Mondelez International, J. M. Smucker, and General Mills could be impacted if it progresses.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D plans to include generic and biosimilar drugs on formularies, directly reducing brand-name drug sales and increasing generic/biosimilar market share. This legislation will decrease pharmaceutical company revenues from patented drugs and lower pharmacy benefit manager (PBM) margins on brand-name drugs.
Fair Compensation for Truck Crash Victims Act
HR8218, the Fair Compensation for Truck Crash Victims Act, has been referred to the House Committee on Transportation and Infrastructure. This bill aims to increase the minimum insurance requirements for motor carriers, which could structurally impact the trucking and insurance sectors.
Most Favored Patient Act of 2026
The Most Favored Patient Act of 2026 (HR7837) has been introduced in the House, proposing a most-favored-nation drug pricing model for Medicare-covered drugs by January 1, 2029. This bill, if enacted, would directly reduce revenue for major pharmaceutical companies by mandating the lowest global drug prices. The bill is currently in the early stages of the legislative process, having been referred to the Committees on Energy and Commerce and Ways and Means.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877, the "Shane DiGiovanna Act," introduced on March 9, 2026, mandates a nationwide Medicaid demonstration program for epidermolysis bullosa wound care, creating a new, guaranteed revenue stream for pharmaceutical and medical supply companies. This bill directly increases demand for specific over-the-counter medications and wound care supplies by expanding covered services under Medicaid.
To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.
The 'Expanding Support for Living Donors Act of 2026' directly increases financial incentives for living organ donation, expanding eligibility and raising reimbursement caps to $10,000 for fiscal year 2027. This will increase the supply of organs for transplant, driving demand for transplant-related medical services and technologies, directly benefiting healthcare companies in diagnostics, procedures, and post-operative care.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "The Fair Credit Reporting Act's Limited Preemption of State Laws".
This joint resolution re-establishes state authority over credit reporting, increasing compliance costs for national lenders and credit reporting agencies. The fragmented regulatory landscape directly impacts profitability for companies operating across state lines. This creates a significant operational burden and reduces efficiency for large financial institutions and credit bureaus.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 stabilizes Medicare reimbursement for cancer treatments in outpatient settings, directly benefiting pharmaceutical and biotech companies focused on oncology. This legislation secures revenue streams for cancer drug manufacturers by creating a predictable financial environment for cancer care providers and drug suppliers. Companies with significant oncology portfolios see immediate upside.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.